Securities Code: 9341

Notice of the 20th Annual General Meeting of Shareholders

Date	Wednesday, June 25, 2025 at 10:00 a.m. (JST) Reception will open at 9:30 a.m.
Venue	Shibuya SOLASTA Conference 4D, Shibuya SOLASTA 4F, 1-21-1, Dogenzaka, Shibuya-Ku, Tokyo
Item 1:	Appropriation of Surplus
Item 2:	Partial Amendments to the Articles of Incorporation
Item 3:	Appointment of Seven Board Directors

[Preliminary questions]
You can submit preliminary questions on a dedicated website from 9:00 a.m. on Tuesday, June 10, 2025 (JST) to 6:00 p.m. on Tuesday, June 17, 2025 (JST).
Please see page 5 of this Notice for further details.

Genova, Inc.

Securities Code: 9341
June 9, 2025
(Date of commencement of electronic provision measures: June 3, 2025)

Dear Shareholders,

Tomoki Hirase
President and Representative Director
Genova, Inc.
2-21-1, Shibuya, Shibuya-Ku, Tokyo

Notice of the 20th Annual General Meeting of Shareholders

We would like to express our sincere appreciation to all our shareholders for your support.
You are cordially invited to attend the 20th Annual General Meeting of Shareholders of Genova, Inc. as per the schedule below.

Upon convening this General Meeting of Shareholders, the Company will take measures for electronic provision with respect to information that constitutes the content of Reference Documents, etc. for the General Meeting of Shareholders (Matters for Electronic Provision). You are kindly requested to check the information by accessing either of the following Company websites on which the information is posted.

The Company's website: https://genova.co.jp/en/ir/news.html/

(To view the information, please visit the above website and choose from the menu "General Meeting of Shareholders.")

Website where materials for general meeting of shareholders are posted:
https://d.sokai.jp/9341/teiji/

Website of the Tokyo Stock Exchange (TSE) (Listed Company Search)
https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show

(Access the TSE website by using the internet address shown above, enter "Genova" in "Issue name (company name)" or the Company's securities code "9341" in "Code," and click "Search." Then, click "Basic information" and select "Documents for public inspection/PR information." Under "Filed information available for public inspection," click "Click here for access" under "[Notice of General Shareholders Meeting /Informational Materials for a General Shareholders Meeting].")

If you are unable to attend the meeting in person, you may exercise your voting rights via the Internet, etc. or by mail. Please read the Reference Documents for the General Meeting of Shareholders, and exercise your voting rights, either by inputting your approval or disapproval on the Company's designated website (https://evote.tr.mufg.jp/) or by indicating your approval or disapproval on the enclosed Voting Rights Exercise Form, by 6:00 p.m., on Tuesday, June 24, 2025 (JST).

Sincerely,

Details

1. Date and Time: Wednesday, June 25, 2025 at 10:00 a.m. (JST)
2. Venue: Shibuya SOLASTA Conference 4D, Shibuya SOLASTA 4F,
2-21-1, Dogenzaka, Shibuya-Ku, Tokyo
(Please see the location map at the end of this notice.)
3. Purposes:
Items to be reported:
1. Business reports and consolidated financial statements for the Company's 20th business term (from April 1, 2024 to March 31, 2025) and audit result reports of consolidated financial statements by the accounting auditor and the Board of Corporate Auditors
2. Reports of non-consolidated financial statements for the Company's 20th business term (from April 1, 2024 to March 31, 2025)

Item to be resolved:
Item 1: Appropriation of Surplus
Item 2: Partial Amendments to the Articles of Incorporation
Item 3: Appointment of Seven Board Directors

4. Management decisions concerning the convocation of the meeting (Information regarding exercise of voting rights, etc.)

(1) Matters omitted from the delivered documents

The following matters are not stated in the documents delivered to shareholders who requested the delivery of documents, in accordance with laws and regulations and the provisions of Article 16 of the Articles of Incorporation of the Company. Accordingly, the documents delivered to shareholders who requested the delivery of documents are part of the documents audited by the corporate auditor and the accounting auditor when preparing audit reports.

(i) Notes to consolidated financial statements in consolidated financial statements
(ii) Notes to non-consolidated financial statements in non-consolidated financial statements
(iii) Statements of changes in shareholders' equity
(iv) Information on the share acquisition rights
(v) Status of accounting auditors
(vi) Systems for ensuring the proper operation of the Company and situations of the operation of the systems

(2) Treatment of a Voting Rights Exercise Form returned without any indication of approval or disapproval

If neither approval nor disapproval of the proposals is indicated, you will be deemed to have indicated your approval.

(3) Treatment of duplicate votes cast both in writing and via the Internet, etc.

If you exercise your voting rights both in writing and via the Internet, etc., the voting rights exercised via the Internet, etc., will be effective.

(4) Treatment of duplicate votes cast via the Internet, etc.

If you have cast your voting rights multiple times via the Internet, etc. only the vote cast last will be treated as valid.

- For the General Meeting of Shareholders, the Company sends to all shareholders documents that include matters related to electronic provision measures, excluding the aforementioned matters, whether the delivery of documents is requested or not.
- If you plan to attend in person, please present the enclosed Voting Rights Exercise Form at the reception desk upon your arrival.
- Any updates to the matters to be provided electronically will be posted on the relevant websites shown above.
- Information for shareholders will be posted on the Company's website (https://genova.co.jp/en/) on the Internet. Please visit the Company's website for the latest information when necessary.



Guidance on Exercising Voting Rights

Voting rights at General Meetings of Shareholders are important rights of you as a shareholder. Please exercise your voting rights after reading and considering the details of the attached Reference Documents for the General Meeting of Shareholders.
The following three ways to exercise your voting rights are available.



If you attend the General Meeting of Shareholders

Please present the voting card at the reception desk upon your arrival.

Date & Time

10 a.m. on Wednesday June 25, 2025
(Reception will open at 9:30 a.m.)



If you exercise voting rights via the Internet

Please follow the instructions on the next page and enter your approval or disapproval for the agendas.

Deadline

Entries completed by 6:00 p.m.,
Tuesday, June 24, 2025



If you exercise voting rights in writing (by mail)

Please state whether you are for or against the agenda items on the enclosed Voting Rights Exercise Form and drop it into a post box. It is not necessary to affix a stamp.

Deadline

Votes reaching us by 6:00 p.m.,
Tuesday, June 24, 2025

Instructions on Filling the Voting Rights Exercise Form



※議決権行使書用紙はイメージです。

こちらに議案の賛否をご記入ください。

第1、2号議案

- 全員賛成の場合 ≫ 「賛」の欄に○印
- 全員反対する場合 ≫ 「否」の欄に○印

第3号議案

- 全員賛成の場合 ≫ 「賛」の欄に○印
- 全員反対する場合 ≫ 「否」の欄に○印
- 一部の候補者に反対する場合 ≫ 「賛」の欄に○印をし、反対する候補者の番号をご記入ください。

On Voting Rights via the Internet

How to read a QR code

You can log into the voting website without entering the login ID and temporary password written on the Voting Rights Exercise Form.

1 議決権行使書用紙に記載のQRコードを読み取ってください。



※「QRコード」は株式会社デンソーウェーブの登録商標です。

2 以降は画面の案内に従って賛否をご入力ください。



For inquiries about operation procedure for exercising voting rights via the Internet using PCs and smartphones, please contact the inquiry desk on the right.

How to enter your login ID and temporary password

Voting website https://evote.tr.mufg.jp/

1 議決権行使ウェブサイトにアクセスしてください。

2 議決権行使書用紙に記載された「ログインID・仮パスワード」を入力しクリックしてください。



3 以降は画面の案内に従って賛否をご入力ください。

※操作画面はイメージです。

Stock Transfer Agency Department,
Mitsubishi UFJ Trust and Banking Corporation (Helpdesk)
0120-173-027
(Toll free, Operating hours: 9:00-21:00)

Institutional investors are permitted to use the platform for the electronic exercise of voting rights for institutional investors operated by ICJ, Inc.

Information about the Acceptance of Preliminary Questions

The Company is accepting questions from shareholders related to the matters to be reported or resolved at the 20th Annual General Meeting of Shareholders ahead of the meeting as described below. The Company will answer some of the preliminary questions received via the following website for acceptance of preliminary questions on the day of the General Meeting of Shareholders.
Please note that the Company will only accept questions related to matters to be reported or resolved at the General Meeting of Shareholders and cannot provide individual responses to questions.

Website for acceptance of preliminary questions

https://forms.gle/Gtwpo28QhkRbhpkT6

* Please access the above website and, using the form, enter:

- your name;
- your shareholder number (the eight-digit number shown in the top center of the Voting Rights Exercise Form); and
- your question.

➢ Period for acceptance of preliminary questions

From 9:00 a.m. on Tuesday, June 10, 2025 (JST) to 6:00 p.m. on Tuesday, June 17, 2025 (JST)

Reference Documents for the General Meeting of Shareholders

Item 1: Appropriation of Surplus

The Company considers the enhancement of corporate value through business expansion to be its top priority and positions the return of profit to shareholders as a key management initiative in this context. Accordingly, the Company has a basic policy of striving to maintain stable dividends while paying attention to the buildup of retained earnings.
In July this year, the Company will celebrate the 20th anniversary of its establishment and as an expression of appreciation for the support of shareholders to date and in comprehensive consideration of a range of factors including financial results for the fiscal year under review and future business expansion, the Company proposes paying a year-end dividend for the fiscal year under review as follows, adding a commemorative dividend of ¥20 to an ordinary dividend (first dividend) of ¥10.

(1) Type of dividend property
Cash
(2) Allotment of dividend property to shareholders and total amount
¥30 per common share of the Company (including a dividend in commemoration of the Company's 20th anniversary of ¥20)
Total dividends: 519,195,960 yen
(3) Effective date of dividends of surplus
June 26, 2025

Item 2: Partial Amendments to the Articles of Incorporation

1. Reason for the proposal

In connection with the business transfer described in the “Notice Regarding Business Acquisition” dated April 11, 2025, certain items will be added to Article 2 (Purpose) of the Articles of Incorporation to incorporate the relevant business activities and to clarify the operation of a secondhand goods business.

2. Details of amendments

The details of the amendments are shown below.

(The underlined parts show the change.)

Current Articles of Incorporation	Proposed Amendments
Chapter 1. General Provisions	Chapter 1. General Provisions
Article 1 (Omitted)	Article 1 (Unchanged)
(Purpose)	(Purpose)
Article 2. The purpose of the Company shall be to engage in the following businesses:	Article 2 (Unchanged)
(1) to (12) (Omitted)	(1) to (12) (Unchanged)
(Newly established)	(13) Development, manufacturing, leasing, rental, sale, repair, maintenance, and inspection of various dental equipment
(Newly established)	(14) Planning, design, and construction of interior and exterior of dental clinics
(Newly established)	(15) Consulting services related to dental clinics
(Newly established)	(16) Manufacturing, leasing, rental, sale, repair, maintenance, and inspection of medical-related equipment and materials
(Newly established)	(17) Development, manufacturing, and sale of pharmaceuticals, quasi-drugs, cosmetics, and related chemical industrial products
(Newly established)	(18) Purchase, sale, and exchange of secondhand goods and consignment thereof under the Act on Secondhand Articles
(13) (Omitted)	(19) (Unchanged)

Item 3: Appointment of Seven Board Directors

The terms of office of all (seven) Board Directors will expire at the conclusion of this year's Annual General Meeting of Shareholders. Accordingly, the Company proposes the election of seven Board Directors (four reappointments and three new appointments).
The candidates for Board Directors are as follows:

Candidate Number	Name	Current positions at the Company			
1	Tomoki Hirase	President and Representative Director	Reappointment		
2	Akinao Ueda	Board Director, Executive Officer and General Manager, Finance Department	Reappointment		
3	Koji Takeda	Board Director, Executive Officer and General Manager, Accounting Department	Reappointment		
4	Sho Inoue	Head of Business Promotion Office	New appointment		
5	Yuki Sagehashi	Director	Reappointment	Outside	Independent
6	Yuki Sunada (Yuki Sato)	-	New appointment	Outside	Independent
7	Tetsuya Sano	-	New appointment	Outside	Independent

Reappointment	Candidate for Board Director to be reelected	New appointment	Candidate for Board Director to be newly elected
Outside	Candidate for External Board Director	Independent	Independent officer as provided for by the stock exchange

<table>
<tr><td rowspan="2">No.</td><td>Name
(Date of birth)</td><td>Career summary, and position and responsibilities in the Company
(Significant important positions outside the Company)</td><td>Number of the Company’s shares owned</td></tr>
<tr><td rowspan="2">1</td><td rowspan="2">(Reappointment)
Tomoki Hirase
(February 5, 1978)</td><td>Dec. 1997 Joined Telewave, Inc.
Apr. 2000 Director of Telewave Links, Inc.
Jun. 2001 Managing Director of Telewave Links, Inc.
Jul. 2005 Established the Company, President and Representative Director (current position)
Apr. 2013 Outside Director of Yokohama Fulie Sports Club Co., Ltd.
Aug. 2021 Board of Educational Foundation Japan Sweden Dental Academic Society
Aug. 2023 Representative Director of Hirase Shoten Inc. (current position)
Mar. 2025 Director of Genova Design Co., Ltd. (current position)</td><td rowspan="2">5,602,700</td></tr>
<tr><td>(Significant concurrent positions outside the Company)
Representative Director, Hirase Shoten Inc.
Director, Genova Design Co., Ltd.</td></tr>
<tr><td></td><td colspan="3">Reason for nomination
The Company nominated Tomoki Hirase as a candidate for Board Director and proposes his reappointment as Board Director because the Company considers him essential for the Company’s management given that, since the Company’s establishment in 2005, he has directed the management of the Group, driven the Company’s growth, and has a wealth of knowledge and broad insight in corporate management and business strategy.</td></tr>
<tr><td rowspan="3">2</td><td rowspan="2">(Reappointment)
Akinao Ueda
(March 6, 1986)</td><td>Apr. 2010 Joined JPMorgan Securities Japan Co., Ltd.
Mar. 2015 Joined Mizuho Securities Co., Ltd.
Aug. 2020 Joined Credit Suisse Securities (Japan) Limited.
May 2023 Joined the Company
Executive Officer, General Manager, Finance Department
Jan. 2024 Senior Executive Officer, General Manager, Finance Department
Jun. 2024 Board Director, Executive Officer, and General Manager, Finance Department (current position)</td><td rowspan="2">0</td></tr>
<tr><td>(Significant concurrent positions outside the Company)
Representative Partner, Ueda Capital GK</td></tr>
<tr><td></td><td colspan="3">Reason for nomination
The Company nominated Akinao Ueda as a candidate for Board Director and proposes his reappointment as Board Director because the Company considers him essential for the Company’s management given that he leverages his professional experience at domestic and foreign securities companies and has a wealth of knowledge and broad insight required to strengthen administrative systems and exercise oversight.</td></tr>
</table>

No.	Name (Date of birth)	Career summary, and position and responsibilities in the Company (Significant important positions outside the Company)	Number of the Company's shares owned
3	(Reappointment) Koji Takeda (January 13, 1982)	Dec. 2007 Joined Tohmatsu & Co. (current Deloitte Touche Tohmatsu LLC) Apr. 2018 Joined the Company General Manager, Accounting Department Jun. 2018 Board Director Jul. 2018 Board Director, General Manager, Finance & Accounting Department, and General Manager, General Affairs Department Apr. 2019 Board Director, General Manager, Finance & Accounting Department, and General Manager, General Affairs Department, and General Manager, Operations Department Jun. 2019 Managing Director, General Manager, Finance & Accounting Department, and General Manager, General Affairs Department, and General Manager, Operations Department Jul. 2019 Managing Director, General Manager, Administrative Division, and General Manager, Finance & Accounting Department, and General Manager, Human Resources & General Affairs Department, and General Manager, Operations Department Jun. 2020 Board Director, Executive Officer and General Manager, Administrative Division, and General Manager, Finance & Accounting Department, and General Manager, General Affairs & Labor Relations Department, and General Manager, Operations Department Jul. 2020 Board Director, Executive Officer and General Manager, Finance & Accounting Department, and General Manager, General Affairs & Labor Relations Department, and General Manager, Operations Department Oct. 2020 Board Director, Executive Officer and General Manager, General Affairs & Labor Relations Department Sep. 2021 Board Director, Executive Officer Apr. 2022 Board Director, Executive Officer, and Head of the IPO Preparation Office Sep. 2023 Board Director, Executive Officer and General Manager, Accounting Department (current position)	50,000
	Reason for nomination The Company nominated Koji Takeda as a candidate for Board Director and proposes his reappointment as Board Director because the Company considers him essential for the Company's management given that, since joining the Company, he has been responsible for the finances, accounting, human resources and operations of the entire Group, and has the knowledge and broad insight necessary for the Group's management.		

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, and position and responsibilities in the Company
(Significant important positions outside the Company)</th><th>Number of the Company’s shares owned</th></tr>
<tr><td rowspan="2">4</td><td rowspan="2">(New appointment)
Sho Inoue
(March 24, 1984)</td><td>Apr. 2009 Medical Intern, Yokohama Rosai Hospital
Jul. 2011 Research/Teaching Assistant, Yokohama City University Medical-Engineering Collaboration Global Center of Excellence (COE) program
May 2015 Representative Director, MedicalNote, Inc.
Apr. 2018 Steering Committee Member, Japan Council for Quality Health Care (current position)
Jun. 2020 Trustee, Yokohama Foundation for Advancement of Medical Science (current position)
Mar. 2024 Guest Associate Professor, Osaka University
Oct. 2024 Project Associate Professor, Yokohama City University (current position)
Jan. 2025 Visiting Fellow, Kyoto University (current position)
May 2025 Joined the Company,
Head of Business Promotion Office (current position)</td><td rowspan="2">0</td></tr>
<tr><td>(Significant concurrent positions outside the Company)
Steering Committee Member, Japan Council for Quality Health Care
Trustee, Yokohama Foundation for Advancement of Medical Science
Project Associate Professor, Yokohama City University
Visiting Fellow, Kyoto University
Part-time Lecturer, Institute of Science Tokyo
Trustee, Japanese Society for Digital Medicine and Healthcare</td></tr>
<tr><td></td><td colspan="3">Reason for nomination
The Company nominated Sho Inoue as a candidate for Board Director because he has a broad knowledge and network in the fields of policy and academia, gained through working as a medical doctor and pursuing a pHD in medicine, engaging in clinical, educational and research activities in his current university posts, and extensive experience serving as a member and advisor for public institutions and scientific organizations. The Company also considers him to be extremely significant for the Company’s efforts to create further value in the medical field, given his long involvement in the management of medical-related business and his extensive experience of developing business and building alliances. The Company proposes that he be elected as Board Director in the expectation that he will leverage this expertise and experience to help further strengthen business in the medical field and enhance corporate value.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, and position and responsibilities in the Company
(Significant important positions outside the Company)</th><th>Number of the Company’s shares owned</th></tr>
<tr><td rowspan="2">5</td><td rowspan="2">(Reappointment)
Yuki Sagehashi
(January 2, 1982)</td><td>Jun. 2003 Established Medicis Inc., Representative Director
Mar. 2012 Auditor, One-for-all Co., Ltd. (current position)
Sep. 2014 Director, Hospital based Kids Art Project (current position)
Sep. 2016 Established Japan Preventive Medicine Association, Representative Director (current position)
May 2017 Established Japan Medical Venture Association, Director (current position)
Jun. 2018 Board Director, the Company (current position)
Jun. 2019 President and CEO, Data Index Corporation (current position)
Jun. 2021 Representative Director, International Medicine and Health Institute (current position)</td><td rowspan="2">200,000</td></tr>
<tr><td>(Significant concurrent positions outside the Company)
President and CEO, Data Index Corporation
Representative Partner, JSH Holdings LLC
Representative Partner, JSH Holdings No.2 LLC
Representative Director, Japan Preventive Medicine Association
Representative Director, International Medicine and Health Institute
Director, Japan Medical Venture Association
Director, Hospital based Kids art project
Member, X Capital LLP
Auditor, One-for-all Co., Ltd.</td></tr>
<tr><td></td><td colspan="3">[Reasons for nomination and overview of expected roles]
The Company nominated Yuki Sagehashi as a candidate for External Board Member because she has extensive connections with medical professionals and insight in the medical industry gained from establishing medical institutions and supporting their management and expanding a pharmaceutical insert database business, and the Company expects her to provide oversight and advice, etc. on the Company’s business execution as a medical industry expert. If the proposal is approved, the Company expects her to be involved in the selection of officers of the Company and the determination of officers’ remuneration, etc. from a neutral and objective perspective as a member of the Nomination and Remuneration Committee.</td></tr>
</table>

No.	Name (Date of birth)	Career summary, and position and responsibilities in the Company (Significant important positions outside the Company)	Number of the Company's shares owned
6	(New appointment) Yuki Sunada (Yuki Sato) (May 27, 1977)	Oct. 2005 Joined Yamamoto Sogo Law Office (now Yamamoto Shibasaki Law Office) May 2006 Joined White & Case LLP Oct. 2013 Partner, NAMURA & PARTNERS Legal Professional Corporation (currently Toranomon Chuo Law Firm) Sep. 2014 Part-time lecturer, Rokyo University Nov. 2014 Director, T&C Consulting Co. Ltd. Mar. 2015 Auditor, Save the Children Japan May 2015 Outside Auditor, Hatena Co., Ltd. (current position) Jun. 2016 Outside Auditor, ZUU Co., Ltd. Jun. 2016 Auditor, JOSUIKAI, Inc. Sep. 2016 Outside Auditor, DLE, Inc. Dec. 2016 Partner, King & Wood Mallesons Sep. 2018 Auditor, Japan Social Innovation and Investment Foundation Oct. 2018 Outside Director (Audit & Supervisory Committee Member), Net Protections Holdings, Inc. (current position) Jan. 2019 Partner, So & Sato Law Offices Jun. 2020 Auditor, Hitotsubashi Daigaku Koenkai (current position) Jun. 2020 Representative Partner, So & Sato Law Offices (current position) Nov. 2021 Outside Director, coconala Inc. Apr. 2024 Auditor, Topaz Regional Partners Inc. (current position)	0
		(Significant concurrent positions outside the Company) Outside Auditor, Hatena Co., Ltd. Outside Director (Audit & Supervisory Committee Member), Net Protections Holdings, Inc. Representative Partner, So & Sato Law Offices	
	[Reasons for nomination and overview of expected roles] The Company nominated Yuki Sunada as a candidate for External Board Director in the expectation of benefiting from her extensive experience and deep insight as a lawyer and her knowledge and guidance which is backed by her experience serving as an Auditor at other companies and will help strengthen the oversight function of the Board of Directors and realize fair and transparent management. If the proposal is approved, the Company expects her to be involved in the selection of officers of the Company and the determination of officers' remuneration, etc. from a neutral and objective perspective as a member of the Nomination and Remuneration Committee.		

No.	Name (Date of birth)	Career summary, and position and responsibilities in the Company (Significant important positions outside the Company)	Number of the Company's shares owned
7	(New appointment) Tetsuya Sano (January 16, 1970)	Oct. 1992 Joined Tohmatsu & Co. (current Deloitte Touche Tohmatsu LLC) Jun. 1996 Registered as certified public accountant May 2000 Established and joined FreeBit Co., Ltd. Jul. 2001 Director, CFO Aug. 2005 Established Growin' Partners Inc., Representative Director (current position) Sep. 2014 Outside Auditor, BrainPad Inc. Aug. 2015 Outside Auditor, ZUU Co., Ltd. Sep. 2017 Outside Director, BrainPad Inc. Jun. 2022 Outside Director (Audit & Supervisory Committee Member), ZUU Co., Ltd. Sep. 2024 Outside Director, BrainPad Inc. (current position) (Significant concurrent positions outside the Company) Representative Director, Growin' Partners Inc. Outside Director, BrainPad Inc.	0
	[Reasons for nomination and overview of expected roles] The Company nominated Tetsuya Sano as a candidate for External Board Director because he has multi-faceted insight, including a wealth of expertise and experience as a certified public accountant, extensive business experience as an entrepreneur and corporate manager, and involvement in M&A support and listing support services and independent committees in TOBs, and the Company expects to gain objective and clear advice and recommendations on the Company's management in general from him. If the proposal is approved, the Company expects him to be involved in the selection of officers of the Company and the determination of officers' remuneration, etc. from a neutral and objective perspective as a member of the Nomination and Remuneration Committee.	

(Notes) 1. Each candidate does not have any special interest in the Company.
2. Mr. Tomoki Hirase is the Company's largest shareholder.
3. Ms. Yuki Sagehashi is currently the Company's External Board Director and will have served as External Board Director for seven years upon the conclusion of this General Meeting of Shareholders.
4. Ms. Yuki Sagehashi, Ms. Yuki Sunada, and Mr. Tetsuya Sano are candidates for External Board Director.
5. The Company has executed an agreement with Ms. Yuki Sagehashi on the limitation of liability for damages as provided for under the provisions of Paragraph 1, Article 423 of the Companies Act according to the provisions of Paragraph 1, Article 427 thereof. The maximum amount of liability based on this agreement shall be the minimum amount stipulated in Article 425, Paragraph 1 of the Companies Act. If her reappointment is approved, the agreements will continue.
6. If the elections of Ms. Yuki Sunada, and Mr. Tetsuya Sano are approved, the Company will enter into a liability limitation agreement with each of them pursuant to Article 427, Paragraph 1 of the Companies Act, limiting their liability for damages as provided for under Article 423, Paragraph 1 of the Companies Act.
7. The Company has entered into an agreement on officer indemnification insurance set forth in Article 430-3,

Paragraph 1 of the Companies Act with an insurance company. An overview of the insurance policy is described in the business report in 2. Current Status of the Company (3) (iii) An overview of the officer indemnification insurance policy. The candidates will be the insured under the insurance policy if they are appointed and take office as a Board Director. The Company plans to renew the policy with the same conditions at the time of next renewal.

8. The Company has registered Ms. Yuki Sagehashi as an Independent Officer pursuant to the provisions of TSE. The Company will continue to designate her as an Independent Officer if her reappointment is approved. Since Ms. Yuki Sunada and Mr. Tetsuya Sano satisfy the requirements for an Independent Officer stipulated by TSE, the Company plans to register them with TSE as Independent Officers.